FDA investigates potential tumour risk following SMA gene therapies
The US Food and Drug Administration is investigating a potential risk of tumour formation associated with Zolgensma and Itvisma gene therapies for spinal muscular atrophy, following evidence of viral vector DNA integration into patients' genomes...




